Abstract 4096
Background
CAPRI, a randomized phase III trial comparing: an intervention combining Nurse Navigators (NNs) and a mobile application vs. Standard of care in cancer patients treated with oral anticancer agents was initiated in 2016 at Gustave Roussy (Villejuif, France). NNs provide regular telephone follow-ups to manage patients’ symptoms and assess toxicities, adherence to treatment and supportive care needs. Patients have access to a mobile application to record tracking data, contact NNs via secure messaging, view therapy and side effect information or store documents. Patient can contact the NNs on a dedicated phone line or by email/secure messaging
Methods
The present analysis involves 3 main data sources: - A questionnaire sent to patients after using for 5 months the CAPRI intervention in order to assess their experience, - Interviews conducted with patients to obtain their feedback of the intervention, - Data extraction from the application and NNs’ interventions over a 24-month period.
Results
Overall, 166 patients (83%) filled the questionnaire. Fifteen interviews were conducted. Patients’ experience with CAPRI intervention is summarized in the table below.Table: CN12
Items | % of patients strongly agree or agree |
---|---|
CAPRI intervention is useful | 96 |
Communicating with the NNs is a reassuring experience | 98 |
CAPRI intervention helps me to better manage my treatment | 79 |
CAPRI intervention is helpful in managing the side effects of my treatment | 87 |
CAPRI intervention helps me to become involved in my treatment | 81 |
CAPRI intervention responds to my expectations and needs for care | 90 |
I am satisfied with the responses from the NNs | 91 |
CAPRI intervention is overly constraining | 9 |
The open-ended comments on the questionnaires and interviews with patients highlighted the importance of listening, having a contact person who is easily reachable, available and empathetic. Concerning the use of the mobile application, 53% of patients reported having tried to connect and only 38% reported monitoring data at least once. By focusing on patient-NNs communication during the study period (817 requests), most contacts are performed by phone (78%) or e-mail (18%) but very few by secure messaging (4%).
Conclusions
Patients’ experience about the intervention was strongly positive. However, the mobile application is poorly used, suggesting that from the patients’ perspective, the presence of NNs is the key of the intervention.
Clinical trial identification
2016-A00254-47.
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
Fondation Philanthropia - Lombard Odier, Agence Nationale de la Recherche IHU-MMO, ARS Ile de France, Novartis, AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract